MedTrace Logo

Glucose-dependent Insulinotropic Polypeptide (GIP) and Lipid Metabolism

NCT00999271 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2009-10-21

No results posted yet for this study

Summary

The aim of this proposal is to examine whether endogenous GIP and exogenous GIP alone and in combination with insulin affect gastric emptying (GE), appetite, energy intake, energy expenditure (EE) and plasma levels of triglycerides (TAG), free fatty acids FFA) and glycerol in man.

Conditions

  • Healthy Subjects

Interventions

OTHER

Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)

two different dosages: * 0.8 pmol/kg/min * 1.5 pmol/kg/min for 300 minutes

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00999271 on ClinicalTrials.gov